These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 11977554)
1. [The incidence of phlebitis in the patients administrated vinorelbine by intravenous bolus injection--a retrospective study]. Nakayama S; Matsubara N; Sakai T; Aso N Gan To Kagaku Ryoho; 2002 Apr; 29(4):633-5. PubMed ID: 11977554 [No Abstract] [Full Text] [Related]
2. Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity. Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Saijo N; Nishiwaki Y Lung Cancer; 2007 Mar; 55(3):337-41. PubMed ID: 17126951 [TBL] [Abstract][Full Text] [Related]
3. [Phlebitis after vinorelbine]. Sauter C; Margulies A; Pestalozzi B Schweiz Med Wochenschr; 1998 Feb; 128(9):343. PubMed ID: 9544462 [No Abstract] [Full Text] [Related]
4. Vinorelbine and venous irritation: optimal parenteral administration. de Lemos ML J Oncol Pharm Pract; 2005 Jun; 11(2):79-81. PubMed ID: 16460608 [TBL] [Abstract][Full Text] [Related]
5. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial. Hirsh V; Desjardins P; Needles BM; Rigas JR; Jahanzeb M; Nguyen L; Zembryki D; Leopold LH Am J Clin Oncol; 2007 Jun; 30(3):245-51. PubMed ID: 17551300 [TBL] [Abstract][Full Text] [Related]
6. High body mass index correlates with increased risk of venous irritation by vinorelbine infusion. Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Nishiwaki Y Jpn J Clin Oncol; 2004 Apr; 34(4):206-9. PubMed ID: 15121757 [TBL] [Abstract][Full Text] [Related]
7. Adynamic ileus in a patient with non-small-cell lung cancer after treatment with vinorelbine. Liebmann J; Friedman K Am J Med; 1996 Dec; 101(6):658-9. PubMed ID: 9003116 [No Abstract] [Full Text] [Related]
8. [Consideration of preventive free-flowing IV infusion method for vinorelbine]. Suga Y; Hara Y; Hashimoto H; Nishigami J; Shimizu M; Akasaka H; Hayashi K; Yonejima M; Nakamura M; Inokuchi M; Kasahara K; Nishimura G; Miyamoto K Gan To Kagaku Ryoho; 2007 Aug; 34(8):1255-7. PubMed ID: 17687207 [TBL] [Abstract][Full Text] [Related]
10. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. Gridelli C; Manegold C; Mali P; Reck M; Portalone L; Castelnau O; Stahel R; Betticher D; Pless M; Pons JT; Aubert D; Burillon JP; Parlier Y; De Marinis F Eur J Cancer; 2004 Nov; 40(16):2424-31. PubMed ID: 15519515 [TBL] [Abstract][Full Text] [Related]
11. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. Westeel V; Quoix E; Moro-Sibilot D; Mercier M; Breton JL; Debieuvre D; Richard P; Haller MA; Milleron B; Herman D; Level MC; Lebas FX; Puyraveau M; Depierre A; J Natl Cancer Inst; 2005 Apr; 97(7):499-506. PubMed ID: 15812075 [TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057 [TBL] [Abstract][Full Text] [Related]
13. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study. Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N J BUON; 2007; 12(1):33-9. PubMed ID: 17436399 [TBL] [Abstract][Full Text] [Related]
14. Oral versus intravenous vinorelbine: clinical safety profile. Gebbia V; Puozzo C Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453 [TBL] [Abstract][Full Text] [Related]
15. [Prophylaxis of toxic effects on the peripheral venous system associated with intravenous administration of vinorelbine]. Cinieri S; Orlando L; Cocorocchio E; Munzone E; Catania C; Brunetti C; Rocca A; Martinelli G; Nolè F Clin Ter; 1999; 150(3):225-9. PubMed ID: 10528436 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of a biweekly regimen of vinorelbine and cisplatin in advanced non-small cell lung cancer. Chen CH; Lin CM; Kao KC; Chang JW; Tsao TC Chang Gung Med J; 2007; 30(3):249-55. PubMed ID: 17760276 [TBL] [Abstract][Full Text] [Related]
18. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Jensen LH; Osterlind K; Rytter C Lung Cancer; 2008 Oct; 62(1):85-91. PubMed ID: 18372075 [TBL] [Abstract][Full Text] [Related]
19. Phase II study of the combination of vinorelbine and cisplatin in advanced non-small-cell lung cancer. Mori K; Kamiyama Y; Kondo T; Kano Y; Tominaga K Cancer Chemother Pharmacol; 2004 Feb; 53(2):129-32. PubMed ID: 14605861 [TBL] [Abstract][Full Text] [Related]
20. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance. Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]